Navigation Links
JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
Date:7/9/2009

Women with hormone receptor (HR) negative first tumors have twice as much risk for developing a second breast cancer as women with HR-positive tumors, according to a study published online July 9 in the Journal of the National Cancer Institute.

Christina A. Clarke, Ph.D., of the Northern California Cancer Center in Fremont, Calif., and colleagues examined data from the National Cancer Institute's Surveillance, Epidemiology, and End Results database to analyze whether a first tumor's estrogen receptor and progesterone receptor content and the age or race of the woman has anything to do with her risk of a second tumor.

They found that women who have had breast cancer are at increased risk of a second primary breast cancer, compared with risk in the general population. They also found that women whose first tumors were hormone-receptor negative, compared with those whose tumors were hormone-receptor positive, had almost twice as much risk of any second breast cancer, and a five-fold increase in risk of a second hormone-receptor negative breast cancer.

"Future research should focus on identifying genetic factors that predispose women to multiple HR-negative tumors to target screening, prevention, and treatment strategies more effectively," the author writes.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. In brief: New prognostic indicator for patients with IPF
2. JNCI news brief: Improving the biomarker pipeline for early cancer detection
3. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
4. Survival differences by race most apparent in advanced stages of breast cancer
5. MRI finds breast cancer before it becomes dangerous
6. Pathway links inflammation, angiogenesis and breast cancer
7. Drop in breast cancer incidence linked to hormone use, not mammograms
8. Breast cancer prevention practices vary across Canada
9. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
10. Acrylamide Wont Raise Breast Cancer Risk
11. New link between estrogen and breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology: